Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and tolerablilty of HPV mRNA vaccine in HPV-driven squamous cell carcinoma.

Trial Profile

Safety and tolerablilty of HPV mRNA vaccine in HPV-driven squamous cell carcinoma.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 113 (Primary)
  • Indications Carcinoma; Cervical cancer; Head and neck cancer; Penile cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HARE-40
  • Most Recent Events

    • 05 May 2021 Status changed from suspended to active, no longer recruiting.
    • 24 Mar 2020 Status changed from recruiting to suspended.
    • 24 Mar 2020 Planned End Date changed from 31 Jan 2023 to 1 Dec 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top